查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1638905

2024 - 2032 年核醫市場機會、成長動力、產業趨勢分析與預測

Nuclear Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球核子醫學市場將於2023 年達到136 億美元，並有望強勁成長，預計2024 年至2032 年複合年成長率為16.3%。強勁需求診斷技術與放射性藥物的持續創新。隨著醫療保健提供者和患者越來越優先考慮先進的診斷和治療選擇，這些因素對市場擴張做出了重大貢獻。

各國政府和研究組織廣泛投資於核子醫學研究和開發。這些投資旨在加強醫療基礎設施、擴大診斷範圍並改善公共衛生結果。已開發國家已啟動國家舉措，為尖端成像技術和放射性藥物基礎設施提供資金，提高診斷能力並支持核醫解決方案的採用。

從細分市場來看，市場分為診斷和治療，診斷細分市場到2023 年將產生94 億美元的收入。地獲得先進的核子成像工具。這些地區慢性病發病率的上升進一步推動了對核子診斷的需求。核子造影方法，特別是心肌灌注造影（MPI），透過評估血流、識別心臟病和評估心臟功能，在心臟病學中發揮至關重要的作用。隨著生活方式的改變和人口老化導致全球心臟病盛行率上升，透過核診斷進行心臟影像的需求不斷增加。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 136 億美元
預測值 547 億美元
複合年成長率 16.3%

根據最終用途，核醫市場涵蓋醫院、診斷中心、研究機構和其他設施。醫院是 2023 年的主導部分，預計到 2032 年將達到 333 億美元。醫院也擴大採用混合成像系統，例如 PET/CT、SPECT/CT 和 PET/MRI，這些系統透過整合解剖和功能性影像來提高診斷精度。這些複雜的系統通常安裝在資源豐富的醫院環境中，導致患者數量增加。

2023 年，北美核醫收入達70 億美元，預計到2032 年複合年成長率為15.6%。成像系統。北美設備齊全的醫院、專科診所和診斷中心非常適合整合先進的核子醫學解決方案。此外，人口老化越來越容易患慢性和與年齡相關的疾病，包括阿茲海默症和各種癌症，這進一步擴大了對核診斷用於早期檢測和個人化治療策略的需求。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 慢性病盛行率不斷上升
      • 核子醫學技術不斷進步
      • 醫療保健支出增加
      • 有利的政府舉措
    • 產業陷阱與挑戰
      • 放射治療費用高
      • 放射性藥物的半衰期短
  • 成長潛力分析
  • 監管環境
  • 報銷場景
  • 技術景觀
    • 核心技術
    • 鄰近技術
  • 未來市場趨勢
  • 管道分析
  • 波特的分析
  • PESTEL分析
  • 差距分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

  • 主要趨勢
  • 診斷
    • 單光子發射電腦斷層掃描 (SPECT) 同位素
      • TC-99m
      • I-123
      • GA-67
      • TL-201
      • 其他 SPECT 同位素
    • 正子斷層掃描 (PET) 同位素
      • F-18
      • RB-82
      • 其他 PET 同位素
  • 療法
    • 貝塔發射體
      • I-131
      • 盧-177
      • Y-90
      • SM-153
      • 重新186
      • 其他BETA發射體
    • 近距離放射治療同位素
      • 銥192
      • 碘125
      • 銫131
      • 鈀103
      • 其他近距離放射治療同位素
    • 阿爾法發射器
      • RA-223
      • 其他阿爾法發射體

第 6 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 神經病學
  • 心臟病學
  • 腫瘤學
  • 甲狀腺
  • 肺部
  • 其他應用

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 診斷中心
  • 科學研究機構
  • 其他最終用戶

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 9 章：公司簡介

  • Actinium Pharmaceuticals
  • Boston Scientific
  • Bracco
  • Cardinal Health
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma
  • Lantheus
  • Novartis
  • RadioMedix
  • RLS Radiopharmacies
  • Siemens Healthineers
  • Sirtex
  • Sun Pharma
  • Theragenics
簡介目錄
Product Code: 12229

The Global Nuclear Medicine Market reached USD 13.6 billion in 2023 and is poised for robust growth, with a projected CAGR of 16.3% from 2024 to 2032. Key growth drivers include the rising incidence of cancer and cardiovascular diseases, a strong demand for non-invasive diagnostic techniques, and continuous innovation in radiopharmaceuticals. These factors contribute significantly to market expansion as healthcare providers and patients increasingly prioritize advanced diagnostic and therapeutic options.

Governments and research organizations invest extensively in nuclear medicine research and development. These investments aim to enhance healthcare infrastructure, broaden diagnostic access, and improve public health outcomes. Developed countries have launched national initiatives that provide funding for cutting-edge imaging technologies and radiopharmacy infrastructure, advancing diagnostic capabilities and supporting the adoption of nuclear medicine solutions.

Segment-wise, the market is divided into diagnostics and therapeutics, with the diagnostics segment generating USD 9.4 billion in revenue in 2023. Emerging markets are experiencing rising healthcare investments and improved infrastructure, enabling greater access to advanced nuclear imaging tools. Increased rates of chronic diseases in these regions further propel demand for nuclear diagnostics. Nuclear imaging methods, especially myocardial perfusion imaging (MPI), play a crucial role in cardiology by evaluating blood flow, identifying heart diseases, and assessing cardiac function. As lifestyle changes and an aging population drive up heart disease prevalence globally, the need for cardiac imaging through nuclear diagnostics continues to rise.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$13.6 Billion
Forecast Value$54.7 Billion
CAGR16.3%

Based on end-use, the nuclear medicine market spans hospitals, diagnostic centers, research institutes, and other facilities. Hospitals were the dominant segment in 2023 and are projected to reach USD 33.3 billion by 2032. Investments in advanced imaging technologies and the employment of specialized nuclear medicine professionals enable hospitals to offer a broad range of nuclear medicine applications, from diagnostics to theranostics. Hospitals are also increasingly adopting hybrid imaging systems, such as PET/CT, SPECT/CT, and PET/MRI, which enhance diagnostic precision by integrating anatomical and functional imaging. These sophisticated systems are typically housed in well-resourced hospital environments, leading to higher patient volumes.

North America accounted for USD 7 billion in nuclear medicine revenue in 2023, with a forecasted CAGR of 15.6% through 2032. The region's advanced healthcare infrastructure facilitates the adoption of nuclear imaging technologies, especially hybrid imaging systems like PET/CT and SPECT/CT. North America's well-equipped hospitals, specialty clinics, and diagnostic centers are well-suited to integrating advanced nuclear medicine solutions. Additionally, an aging population increasingly susceptible to chronic and age-related conditions, including Alzheimer's and various cancers, further amplifies the demand for nuclear diagnostics for early detection and personalized treatment strategies.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing prevalence of chronic diseases
      • 3.2.1.2 Rising technological advancements in nuclear medicine
      • 3.2.1.3 Rise in healthcare expenditure
      • 3.2.1.4 Favorable government initiatives
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of radiotherapy
      • 3.2.2.2 Short half-life of radiopharmaceuticals
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Reimbursement scenario
  • 3.6 Technology landscape
    • 3.6.1 Core technologies
    • 3.6.2 Adjacent technologies
  • 3.7 Future market trends
  • 3.8 Pipeline analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis
  • 3.11 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Diagnostics
    • 5.2.1 Single Photon Emission Computed Tomography (SPECT) isotopes
      • 5.2.1.1 TC-99m
      • 5.2.1.2 I-123
      • 5.2.1.3 GA-67
      • 5.2.1.4 TL-201
      • 5.2.1.5 Other SPECT isotopes
    • 5.2.2 Positron Emission Tomography (PET) isotopes
      • 5.2.2.1 F-18
      • 5.2.2.2 RB-82
      • 5.2.2.3 Other PET isotopes
  • 5.3 Therapeutics
    • 5.3.1 Beta emitters
      • 5.3.1.1 I-131
      • 5.3.1.2 Lu-177
      • 5.3.1.3 Y-90
      • 5.3.1.4 SM-153
      • 5.3.1.5 Re-186
      • 5.3.1.6 Other beta emitters
    • 5.3.2 Brachytherapy isotopes
      • 5.3.2.1 Iridium-192
      • 5.3.2.2 Iodine-125
      • 5.3.2.3 Cesium-131
      • 5.3.2.4 Palladium-103
      • 5.3.2.5 Other brachytherapy isotopes
    • 5.3.3 Alpha emitters
      • 5.3.3.1 RA-223
      • 5.3.3.2 Other alpha emitters

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Neurology
  • 6.3 Cardiology
  • 6.4 Oncology
  • 6.5 Thyroid
  • 6.6 Pulmonary
  • 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Diagnostic centres
  • 7.4 Research institutes
  • 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 1.1.1 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Actinium Pharmaceuticals
  • 9.2 Boston Scientific
  • 9.3 Bracco
  • 9.4 Cardinal Health
  • 9.5 Curium Pharma
  • 9.6 GE Healthcare
  • 9.7 Jubilant Pharma
  • 9.8 Lantheus
  • 9.9 Novartis
  • 9.10 RadioMedix
  • 9.11 RLS Radiopharmacies
  • 9.12 Siemens Healthineers
  • 9.13 Sirtex
  • 9.14 Sun Pharma
  • 9.15 Theragenics